Spyre Therapeutics, Inc. Common Stock (SYRE)
Health Care – PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 112
- Market Cap
- $7.5B
About Spyre Therapeutics, Inc. Common Stock
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Spyre Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.